Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) – Cantor Fitzgerald upped their FY2017 earnings per share (EPS) estimates for Aquinox Pharmaceuticals in a research report issued on Sunday. Cantor Fitzgerald analyst W. Tanner now expects that the company will earn ($2.06) per share for the year, up from their previous forecast of ($2.36). Cantor Fitzgerald currently has a “Buy” rating and a $28.00 target price on the stock. Cantor Fitzgerald also issued estimates for Aquinox Pharmaceuticals’ FY2018 earnings at ($2.11) EPS.
Several other equities analysts also recently commented on AQXP. Zacks Investment Research downgraded Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 15th. Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 8th. BidaskClub raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Needham & Company LLC reissued a “buy” rating and issued a $25.00 target price on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Finally, ValuEngine cut Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $22.50.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://weekherald.com/2017/11/15/fy2017-eps-estimates-for-aquinox-pharmaceuticals-inc-aqxp-lifted-by-cantor-fitzgerald.html.
Shares of Aquinox Pharmaceuticals (NASDAQ AQXP) opened at $10.43 on Wednesday. Aquinox Pharmaceuticals has a 52-week low of $10.23 and a 52-week high of $19.97.
Several large investors have recently bought and sold shares of AQXP. Alyeska Investment Group L.P. lifted its holdings in Aquinox Pharmaceuticals by 1.8% during the third quarter. Alyeska Investment Group L.P. now owns 282,569 shares of the company’s stock worth $4,010,000 after acquiring an additional 5,046 shares in the last quarter. University of Notre Dame DU Lac lifted its holdings in Aquinox Pharmaceuticals by 11.1% during the third quarter. University of Notre Dame DU Lac now owns 190,283 shares of the company’s stock worth $2,700,000 after acquiring an additional 19,066 shares in the last quarter. Investment Centers of America Inc. bought a new position in Aquinox Pharmaceuticals during the third quarter worth about $175,000. Citadel Advisors LLC bought a new position in Aquinox Pharmaceuticals during the third quarter worth about $194,000. Finally, Sphera Funds Management LTD. lifted its holdings in Aquinox Pharmaceuticals by 21.7% during the third quarter. Sphera Funds Management LTD. now owns 75,535 shares of the company’s stock worth $1,072,000 after acquiring an additional 13,450 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.